What Clinicians Should Know about the QT Interval

JAMA

Volumn 289, Issue 16, 2003, Pages 2120-2127

  Al Khatib, Sana M ^a   Allen LaPointe, Nancy M ^a   Kramer, Judith M ^a   Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; CHLORPROMAZINE; CLARITHROMYCIN; DESIPRAMINE; DISOPYRAMIDE; DOFETILIDE; ERYTHROMYCIN; GATIFLOXACIN; HALOPERIDOL; IBUTILIDE; IMIPRAMINE; KETOCONAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PENTAMIDINE; PIMOZIDE; PROCAINAMIDE; QUINIDINE; RISPERIDONE; SERTRALINE; SOTALOL; SPARFLOXACIN; THIORIDAZINE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE; DRUG;

DRUG INDUCED DISEASE; ELECTROCARDIOGRAPHY MONITORING; HEART RATE; HUMAN; LONG QT SYNDROME; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDLINE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PUBLICATION; REGISTER; RELIABILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TORSADE DES POINTES; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; DRUG MONITORING; ELECTROCARDIOGRAPHY; RISK;

DRUG INTERACTIONS; DRUG MONITORING; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; RISK; TORSADES DE POINTES;

EID: 0242494266     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.16.2120     Document Type: Review

References (58)

1. MedWatch. Glaxo Wellcome voluntarily withdraws Raxar (grepafloxacin) [press release]. Rockville, Md: US Food and Drug Administration; October 1999. Available at: http://www.fda.gov/medwatch/safety/1999/raxar.html. Accessed October 22, 2002.
2. FDA Talk Paper. Janssen Pharmaceutica Stops Marketing Cisapride in the US. Rockville, Md: US Food and Drug Administration; March 2000, Available at: http://www.fda.gov/bbs/topics/answers/ans01007.html. Accessed October 22, 2002.
3. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA. 2000;284: 3036-3039.
4. Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation. 2002;105:794-799.
5. Locati EH, Zareba W, Moss AJ, et al. Age- and sexrelated differences in clinical manifestations in patients with congenital log QT syndrome: findings from the international LQTS Registry. Circulation. 1998; 97:2237-2244.
6. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med. 1998;339:960-965.
7. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89-95.
8. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999;99:529-533.
9. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 1991;84:1136-1144.
10. Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354:1625-1633.
11. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol. 1991;67:774-776.
12. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: how long is prolonged? possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol. 1996;27:76-83.
13. Anderson ME, Al-Khatib SM, Roden DM, Califf RM. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J. 2002;144:769-781.
14. Allen LaPointe N, Al-Khatib SM, Kramer JM, Battle J, Califf RM. Deficits in knowledge related to the QT interval that could impact patient safety [abstract]. J Am Coll Cardiol. 2002;39:125A.
15. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol. 1993; 72:178-228.
16. Hnatkova K, Malik M. "Optimum" formulae for heart rate correction of the QT interval. Pacing Clin Electrophysiol. 1999;22:1683-1687.
17. Aytemir K, Maarouf N, Gallagher MM, Yap YG, Waktare JE, Malik M. Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms. Pacing Clin Electrophysiol. 1999;22:1397-1401.
18. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001;12:411-420.
19. Milne JR, Ward DE, Spurrell RA, Camm AJ. The ventricular paced QT interval: the effects of rate and exercise. Pacing Clin Electrophysiol. 1982;5:352-358.
20. Dofetilide product monograph and confirmation of education. New York, NY: Pfizer Inc; March 2000.
21. Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol. 2000;36:1-12.
22. Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995;92: 2929-2934.
23. Wilde AA, Jongbloed RJ, Doevendans PA, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol. 1999;33:327-332.
24. + channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 1995;92: 3381-3386.
25. Zhang L, Timothy KW, Vincent GM, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation. 2000;102:2849-2855.
26. Donger C, Denjoy I, Berthet M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation. 1997;96:2778-2781.
27. Reardon M, Malik M. QT interval change with age in an overtly healthy older population. Clin Cardiol. 1996;19:949-952.
28. Ahnve S. QT interval prolongation in acute myocardial infarction. Eur Heart J. 1985;6(suppl D):85-95.
29. Rebeiz AG, Al-Khatib SM. A case of severe ischemia-induced QT prolongation. Clin Cardiol. 2001; 24:750.
30. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med. 2002;112:58-66.
31. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983;2:806-817.
32. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med. 1994;331:785-791.
33. Roden DM. Mechanisms and management of proarrhythmia. Am J Cardiol. 1998;82:491-571.
34. Makkar RR, Fromm BS, Steinmen RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
35. Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med. 1997;127:281-284.
36. Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol. 1998;32:169-176.
37. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857-865.
38. Simons GR, Eisenstein EL, Shaw LJ, Mark DB, Pritchett EL. Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias. Am J Cardiol. 1997;80:1551-1557.
39. Clinical Pharmacology [database online]. Tampa, Fla: Gold Standard Multimedia Inc; 2002. Available at: http://cp.gsm.com. Accessed September 17, 2002.
40. USPDI advice for the patient. MICROMEDEX [database online]. Stamford, Conn: Thomson Corp. Healthcare Series Vol 114. Expiration: December 2002. Available at: http://www.micromedex.com. Accessed April 2, 2003.
41. Tatro DS, ed. Drug Interaction Facts. St Louis, Mo: Facts and Comparisons; 2002.
42. Hansten PD, Horn JR. Hansten and Horn's Drug Interactions Analysis and Management. St Louis, Mo: Facts and Comparisons; 2002.
43. Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med. 1999;340:1855-1862.
44. Morganroth J, Goin J. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation. 1991; 84:1977-1983.
45. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation. 1990;82:1106-1116.
46. Waldo AL, Camm AJ, de Ruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7-12.
47. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. Available at: http:// www.fda.gov/cder/calendar/meeting/qt4jam.pdf. Accessed March 25, 2003.
48. Curtis LH, Østbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a large, national outpatient population. Am J Med. 2003;114:135-141.
49. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis. 2001; 43:1-45.
50. Demolis JL, Funck-Brentano C, Ropers J, Ghadanfar M, Nichols DJ, Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation. 1996; 94:1592-1599.
51. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355: 1048-1052.
52. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158:1774-1782.
53. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161-1167.
54. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmias in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325:1070-1074.
55. Anderson ME, Mazur A, Yang T, Roden DM. Potassium current antagonist properties and proarrhythmic consequences of quinotone antibiotics. J Pharmacol Exp Ther. 2001;296:806-810.
56. ICHS7B Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Washington, DC: US Food and Drug Administration; 2002.
57. ICHS7A Safety Pharmacology Studies for Human Pharmaceuticals. Washington, DC: US Food and Drug Administration; 2001.
58. Center for Drug Evaluation and Research home page. Available at: http://www.fda.gov/cder. Accessed March 25, 2003.